Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
0.03
Industry P/E
28.06
Debt to Equity
0
ROE
-2.01 %
ROCE
--
Div. Yield
0 %
Book Value
4.08
EPS
--
CFO
$-25.39 Mln
EBITDA
$-19.45 Mln
Net Profit
$-37.32 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Onconetix
| -88.90 | -41.65 | -85.44 | -98.57 | -- | -- | -- |
|
BSE Sensex*
| 2.54 | 3.39 | 6.46 | 8.82 | 12.19 | 20.38 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
|
|---|---|
|
Onconetix
| -82.00 |
|
S&P Small-Cap 600
| 13.89 |
|
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,904.81 | -- | 38.11 | |
| 71.71 | 7,574.08 | 58.3 | 23.56 | |
| 59.16 | 11,448.88 | 394.4 | 0.76 | |
| 8.13 | 9,704.70 | -- | -3.24 |
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the... treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. Read more
Interim CEO & Chief Science Officer
Dr. Ralph Schiess Ph.D.
Interim CEO & Chief Science Officer
Dr. Ralph Schiess Ph.D.
Headquarters
--
Website
--
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Onconetix Inc stood at $ 79 Mln as on 30-Sep-24
The share price of Onconetix Inc is $0.07 (NASDAQ) as of 25-Apr-2025 16:27 EDT. Onconetix Inc has given a return of -98.57% in the last 1 years.
The P/B ratio of Onconetix Inc is 0.03 times as on , a 99% discount to its peers’ median range of 5.04 times.
Since, TTM earnings of Onconetix Inc is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Onconetix Inc and enter the required number of quantities and click on buy to purchase the shares of Onconetix Inc.
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
The CEO & director of Dr. Ralph Schiess Ph.D.. is Onconetix Inc, and CFO & Sr. VP is Dr. Ralph Schiess Ph.D..
There is no promoter pledging in Onconetix Inc.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Onconetix Inc | Ratios |
|---|---|
|
Return on equity(%)
|
-134.71
|
|
Operating margin(%)
|
-1508.63
|
|
Net Margin(%)
|
-2758.66
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Onconetix Inc was No Profit.
$0.00
(
